|1.||Todorov, Dimiter K: 2 articles (12/2004 - 02/2004)|
|2.||Ilarionova, Maya V: 1 article (12/2004)|
|3.||Konstantinov, Spiro M: 1 article (12/2004)|
|4.||Horvath, Laszlo E: 1 article (12/2004)|
|5.||Seydel, Joachim: 1 article (02/2004)|
|6.||Pajeva, Ilza: 1 article (02/2004)|
01/01/1980 - "Although the drug's true response rate in any given tumor type cannot be determined, its absence of activity in man, to date, and the recent closing of its IND, make further clinical investigation with thalicarpine unlikely."
05/02/1973 - "Total synthesis of the tumor-inhibitory alkaloid thalicarpine."
02/01/2004 - "The results point out to the potential role of the drug-membrane interactions for the effects of doxorubicin and thaliblastine in resistant tumor cells. "
01/01/1993 - "Combination effects of cisplatin (DDP) and thaliblastine (TBL) in DDP-sensitive (0-342) and -resistant (0-342/DDP) rat ovarian tumor cells were investigated. "
01/01/1993 - "Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin."
12/01/2004 - "Additionally, typical for apoptosis oligonucleosomal DNA fragmentation could be detected in leukemia cells treated with thaliblastine. "
12/01/2004 - "Thaliblastine exhibits dose dependent cytotoxic effect on HL-60, HL-60/DOX, RHE and HD-MY-2 leukemia cells. "
12/01/2004 - "Effects of the plant alkaloid thaliblastine on non-cross-resistant and sensitive human leukemia cells in relation with reversal of acquired anthracycline resistance."
12/01/1973 - "Inhibition of macromolecular biosynthesis in cultured L1210 mouse leukemia cells by thalicarpine (NSC 68075)."
|4.||Chromosome Aberrations (Chromosome Abnormalities)
|5.||Breast Neoplasms (Breast Cancer)
11/01/1996 - "Interaction of the Pgp inhibitor, thaliblastine (TBL), with several MDR drugs was therefore investigated in sensitive human breast cancer cell line (MCF-7) as well as adriamycin (AdR) selected MDR subline MCF/AdR. "
09/01/1995 - "Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. "
09/01/1995 - "Thaliblastine (TBL), a plant alkaloid and P-glycoprotein (P-gp) inhibitor, is presently shown to fully reverse 490-fold resistance to Adriamycin (AdR) in a multidrug-resistant (MDR) human breast cancer cell line (MCF/AdR) that overexpresses P-gp, whereas the same treatment had no effect on AdR cytotoxicity in the drug-sensitive parental MCF-7 cells. "
11/01/1996 - "Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells."
|5.||Etoposide (VP 16)